Quetiapine: a new option in bipolar depression

Future Prescriber Pub Date : 2009-12-24 DOI:10.1002/fps.56
Eleni Palazidou MD, PhD, MRCP, FRCPsych
{"title":"Quetiapine: a new option in bipolar depression","authors":"Eleni Palazidou MD, PhD, MRCP, FRCPsych","doi":"10.1002/fps.56","DOIUrl":null,"url":null,"abstract":"<p>Bipolar disorder is a condition characterised by periods of depression, mania or depressive and manic symptoms appearing together. Depression is the predominant symptom and is often responsible for poor quality of life. The condition is treatable, but poor compliance is a major problem. Pharmacological treatments include lithium (although it has poor efficacy in depression), valproate and olanzapine (which can cause metabolic syndrome). In this article, Dr Palazidou considers quetiapine, a second-generation antipsychotic agent, for the treatment of bipolar depression and mania, as well as mixed affective states in bipolar I disorder. Copyright © 2009 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"10 4","pages":"9-14"},"PeriodicalIF":0.0000,"publicationDate":"2009-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.56","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/fps.56","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3

Abstract

Bipolar disorder is a condition characterised by periods of depression, mania or depressive and manic symptoms appearing together. Depression is the predominant symptom and is often responsible for poor quality of life. The condition is treatable, but poor compliance is a major problem. Pharmacological treatments include lithium (although it has poor efficacy in depression), valproate and olanzapine (which can cause metabolic syndrome). In this article, Dr Palazidou considers quetiapine, a second-generation antipsychotic agent, for the treatment of bipolar depression and mania, as well as mixed affective states in bipolar I disorder. Copyright © 2009 John Wiley & Sons, Ltd.

奎硫平:双相抑郁症的新选择
双相情感障碍是一种以抑郁、躁狂或抑郁和躁狂症状同时出现为特征的病症。抑郁是主要症状,通常导致生活质量差。这种情况是可以治疗的,但依从性差是一个主要问题。药物治疗包括锂(尽管它对抑郁症疗效不佳)、丙戊酸盐和奥氮平(可引起代谢综合征)。在这篇文章中,Palazidou博士认为喹硫平是第二代抗精神病药物,可用于治疗双相抑郁和躁狂症,以及双相I型障碍的混合情感状态。版权所有©2009 John Wiley &儿子,有限公司
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信